Bristol-Myers Squibb Company
NYSE: BMY
$58.50
+$0.09 (+0.2%)
Closing Price on November 14, 2024
BMY Articles
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is not getting any great warm welcome out of its 2012 investor meeting webcast. The company may soon find itself in a position where the...
Published:
Last Updated:
U.S. equity markets opened mixed this morning, but some initial enthusiasm wore off by mid-morning and stocks moved slightly lower throughout the day. In Europe, unemployment rose more than expected...
Published:
Last Updated:
These are some of the top analyst upgrades, downgrades and initiations seen in Wall St. research calls this Friday. Active Network Inc. (NYSE: ACTV) raised to Buy at BofA/ML. Allergan Inc. (NYSE:...
Published:
Last Updated:
Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) fell about 80% yesterday after the company revealed that there were discrepancies in the data reported on the company’s Phase II trial of its...
Published:
Vical Inc. (NASDAQ: VICL) is seeing its shares surging higher on news that it has signed a worldwide, nonexclusive licensing pact with drug giant Bristol-Myers Squibb Co. (NYSE: BMY). The pact covers...
Published:
Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen from Wall St. research calls this Tuesday. AngloGold Ashanti Ltd. (NYSE: AU) started as Outperform at Credit Suisse....
Published:
Last Updated:
The three major U.S. stock indexes opened lower this morning but picked up some buying steam in the first hour or so of trading. The morning’s report on durable goods sales looked good until...
Published:
Last Updated:
Jon OggThese are the top analyst calls of upgrades, downgrades and initiations we have seen from Wall St. research calls this Friday morning. Abercrombie & Fitch Co. (NYSE: ANF) maintained...
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) is seeing shares surge today on news that Bristol-Myers Squibb Co. (NYSE: BMY) has run into some unforseen safety issues with a hep-C candidate called INX-189. ...
Published:
Last Updated:
Surging growth of its Cymbalta depression treatment helped Eli Lilly & Co. (NYSE: LLY) beat Wall St.’s earnings expectations. But generic rivals to Plavix, other drugs hurt Bristol-Myers Squibb...
Published:
Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for the first quarter of 2012. The top five sellers include drugs from Bristol-Myers...
Published:
Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but missed slightly on revenues. The drug maker reported...
Published:
What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to wonder which other peers and competitors might be on the M&A block. Monday’s...
Published:
Last Updated:
More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks associated with future regulation under health care, but deals in the biotech and emerging...
Published:
Last Updated:
The freshly announced multibillion biotech buyout of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) for more than $5 billion in equity value may be a bit misleading if you consider that it is...
Published:
Last Updated: